Home Europe EEA Joint Committee Decision of the EEA Joint Committee No 235/2025 of 24 Octobe...
Date: 2026-02-12 Category: Not Applicable State: Union Government Country: Europe

Decision of the EEA Joint Committee No 235/2025 of 24 October 2025 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/205]

Issued by EEA Joint Committee · Not Applicable

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

**Executive Summary** This document is a decision by the EEA Joint Committee (No 235/2025) of 24 October 2025, amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/205]. It incorporates Commission Delegated Regulation (EU) 2025/1475 into the EEA Agreement, pertaining to the inclusion of drug precursors 4-piperidone and 1-boc-4-piperidone in the list of scheduled substances. The decision enters into force on 25 October 2025, contingent upon the completion of all notifications required under Article 103(1) of the EEA Agreement. **Key Points / Main Content** * **Amendment to Annex II:** * Point 15x of Chapter XIII of Annex II to the EEA Agreement is amended to include reference to "32025 R 1475: Commission Delegated Regulation (EU) 2025/1475 of 21 May 2025 (OJ L, 2025/1475, 25.7.2025)." * **Authentic Text:** * The text of Delegated Regulation (EU) 2025/1475 in Icelandic and Norwegian languages is to be published in the EEA Supplement to the Official Journal of the European Union and is authentic. * **Entry into Force:** * This decision enters into force on 25 October 2025, provided that all notifications under Article 103(1) of the EEA Agreement have been made. * **Publication:** * The decision will be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union. **Impact Analysis** **EEA Member States** * **Impact:** EEA Member States are required to incorporate the amendment into their national legislation. * **Action Required:** Ensure national regulations align with the amended Annex II of the EEA Agreement, specifically regarding the inclusion of 4-piperidone and 1-boc-4-piperidone as scheduled substances. **European Commission** * **Impact:** The European Commission is responsible for the initial Delegated Regulation (EU) 2025/1475, which is now being incorporated into the EEA Agreement. * **Action Required:** The Commission is responsible for the publication of the texts in Icelandic and Norwegian. Ensure that relevant documentation is available in all required languages and monitor the implementation of the decision across EEA Member States. **EEA Joint Committee** * **Impact:** Responsible for making the decision to amend the Annex to the EEA Agreement. * **Action Required:** Monitor the notifications under Article 103(1) of the EEA Agreement, and verify their completion, ensuring that the decision enters into force. Publish the decision as required.

Key Entities Referenced

EEA Agreement: The Agreement on the European Economic Area, which this decision amends by updating Annex II regarding technical regulations, standards, testing, and certification. EEA Joint Committee: The committee responsible for making decisions regarding the EEA Agreement. Annex II: A component of the EEA Agreement concerning Technical regulations, standards, testing and certification, which is the subject of amendment by this decision. Commission Delegated Regulation (EU) 2025/1475: A regulation that amends Regulation (EC) No 273/2004, including specific drug precursors in the list of scheduled substances, to be incorporated into the EEA Agreement.
Official Source Record View Original Source →
See Full Document Text
Official Journal EN of the European Union L series 2026/205 12.2.2026 DECISION OF THE EEA JOINT COMMITTEENo 235/2025 of 24 October 2025 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/205] THE EEA JOINT COMMITTEE, Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof, Whereas: (1) Commission Delegated Regulation (EU) 2025/1475 of 21 May 2025 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursors 4-piperidone and 1-boc-4-piperidone in the list of scheduled substances(1) is to be incorporated into the EEA Agreement. (2) Annex II to the EEA Agreement should therefore be amended accordingly, HAS ADOPTED THIS DECISION: Article 1 The following indent is added in point 15x (Regulation (EC) No 273/2004 of the European Parliament and of the Council) of Chapter XIII of Annex II to the EEA Agreement: ‘— 32025 R 1475: Commission Delegated Regulation (EU) 2025/1475 of 21 May 2025 (OJ L, 2025/1475, 25.7.2025).’ Article 2 The text of Delegated Regulation (EU) 2025/1475 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic. Article 3 This Decision shall enter into force on 25 October 2025, provided that all the notifications under Article 103(1) of the EEA Agreement have been made(2). (1) OJ L, 2025/1475, 25.7.2025, ELI: http://data.europa.eu/eli/reg_del/2025/1475/oj. (2) No constitutional requirements indicated. ELI: http://data.europa.eu/eli/dec/2026/205/oj 1/2EN OJ L, 12.2.2026 Article 4 This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union. Done at Brussels, 24 October 2025. For the EEA Joint Committee The President Stefán Haukur JÓHANNESSON 2/2 ELI: http://data.europa.eu/eli/dec/2026/205/oj

Continue your research